News
HER2 status differed between primary tumor and CTCs in 18.8% of women with MBC
The probability of HER2 status discordance decreased with increasing age, but increased with primary tumors that were hormone-receptor positive,...
News
FDA approves biosimilar to bevacizumab
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.
News
ASCO issues guideline on communication with patients
ASCO recommends oncologists establish care goals and address cost of care with each patient.
News
FDA advisory committee to consider adjuvant sunitinib for RCC
Phase 3 results for sunitinib as adjuvant treatment for high risk RCC have been mixed.
News
FDA approves nivolumab for metastatic CRC
The indication includes patients aged 12 years and older with mismatch repair deficient and microsatellite instability high metastatic colorectal...
News
FDA grants priority review of acalabrutinib for second-line treatment of MCL
Acalabrutinib for treatment of patients with mantle cell lymphoma has been granted priority review by the FDA.
News
FDA approves neratinib for extended adjuvant treatment of HER2+ breast cancer
A new approval may help keep HER2+ breast cancer from coming back.
News
FDA approves dabrafenib and trametinib for BRAF V600E+ metastatic NSCLC
The FDA also approved a next-generation sequencing test to detect BRAF and other mutations from a single tissue specimen.
News
FDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLL
Approval provides patients a subcutaneous route for rituximab, significantly reducing the administration time.
Video
VIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017
Expert provides take-home messages on pertuzumab, PARP inhibitors, and CDK4/6 inhibitors.
Video
VIDEO: NCI estimation of MBC numbers a start, but more is needed
SEER data on metastatic breast cancer includes only those diagnosed de novo and not women who were diagnosed following a metastatic recurrence of...
Video
VIDEO: Metastatic Trial Search links MBC patients to relevant trials
CHICAGO – A breast cancer advocate discusses mixed response from physicians and barriers to trial participation faced by patients.
News
FDA approves pembrolizumab for advanced urothelial carcinoma
Pembrolizumab is the third checkpoint inhibitor approved for bladder cancer this month.
News
FDA approves pembrolizumab for first-line advanced NSCLC
The approval was based on an improved overall response rate and progression-free survival in a cohort of 123 patients.
News
FDA approves avelumab for advanced urothelial carcinoma
The drug is approved for second-line use following platinum-containing chemotherapy.